and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing ... PhD (Co-Founder & CEO), a former senior executive at AbbVie with expertise ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

The company plans to analyze the data to determine next steps. AbbVie shares fell as much as 13% as of 11:15 a.m. in New York, their biggest intraday drop since March 2020. The stock had gained 29 ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two mid-stage studies. Truist says that Abbvie’s “pain” is ...

Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today. Read More: Earn up ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the emraclidine Phase 2 data “was certainly disappointing ...

Even before today's trial results, AbbVie lost ground after the U.S. FDA approved Bristol Myers Squibb's (BMY) Cobenfy (xanomeline and trospium chloride) in September as a new schizophrenia treatment.

The company plans to analyze the data to determine next steps. AbbVie shares fell as much as 13% as of 11:15 a.m. in New York, their biggest intraday drop since March 2020. The stock had gained 29% ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

The best-case scenario would be AbbVie determining the study conduct was not proper and that it decides to start a new trial, but even this scenario results in a setback of several years and a ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...